The APOL2 Knockout HeLa Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, with targeted disruption of the APOL2 gene. This format delivers a genetically diverse pool of edited cells, providing a robust and reproducible model for studying APOL2 function without the need for clonal isolation. The polyclonal nature ensures representation of multiple editing events, reducing the risk of clonal artifacts and enabling more physiologically relevant loss-of-function analyses.
HeLa cells are an immortalized epithelial cell line originating from HPV-positive cervical adenocarcinoma. As a cornerstone of cancer research, HeLa cells harbor integrated HPV18 genome, leading to E6-mediated p53 degradation and E7-mediated Rb inactivation, which disrupts key tumor suppressor pathways. Their well-characterized genetics, rapid proliferation, and ease of manipulation make HeLa cells an ideal host for CRISPR-based knockout studies, particularly for exploring mechanisms of cervical cancer progression and therapy resistance.
APOL2 encodes an apolipoprotein that regulates lipid metabolism and cell death. It is transcriptionally activated by p53, TNF-??, and HIF-1??, and functions downstream of these signals to promote intrinsic apoptosis. Mechanistically, APOL2 translocates to mitochondria where it binds anti-apoptotic BCL-2 and BCL-xL, thereby releasing their inhibition on BAX/BAK. This leads to mitochondrial outer membrane permeabilization, cytochrome c release, and caspase-3 activation. APOL2 also modulates autophagy, as reflected by LC3-II conversion, and interacts with BID, linking it to the broader apoptotic network. Key pathway components include p53, APOL2, BCL-2, BAX, caspase-3, and LC3.
In the HeLa cervical adenocarcinoma model, APOL2 knockout offers a unique opportunity to dissect apoptosis and autophagy under conditions of compromised p53 function. Despite HPV E6-mediated p53 attenuation, residual p53 activity can still induce APOL2-dependent apoptosis upon genotoxic insults. Disruption of APOL2 thus helps reveal alternative survival mechanisms employed by cancer cells, including autophagy-mediated cytoprotection. This model is valuable for studying how cervical cancer cells evade cell death and develop resistance to chemotherapeutics such as cisplatin, and for investigating the interplay between apoptosis and autophagy in tumor progression.
This knockout population is suitable for diverse assays, including quantitative RT-qPCR and Western blotting to verify APOL2 depletion and monitor downstream targets like BCL-2, BAX, and caspase-3. Apoptosis can be assessed via flow cytometry with Annexin V/PI staining, while autophagy studies benefit from immunofluorescence detection of LC3 puncta and autophagy flux assays using chloroquine. Co-immunoprecipitation enables analysis of APOL2?CBCL-2 interactions, and drug sensitivity screens (e.g., cisplatin) evaluate chemoresistance. These applications make the cells a versatile tool for apoptosis signaling, autophagy research, and p53 pathway analysis. For further information, contact Ascent Research.
